Document:

bpmc_Ex101

		

			Exhibit 10.1

		

		

			***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406

		

		

			 

		

		
			SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT
		

		
			This Second Amendment, effective April  27, 2016 (“Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together referred to as “Roche”) and Blueprint Medicines, located at 38 Sidney Street, Cambridge, Massachusetts 02139 (“Blueprint”).
		

		
			WHEREAS, Blueprint and Roche entered into a Collaboration and License Agreement dated March 14, 2016, as amended April 15, 2016 (“Agreement”); 
		

		
			WHEREAS, Section 4.1.6 of the Agreement states that “Part 2 shall start with Screening of Library Compounds selected by both Parties”;
		

		
			NOW THEREFORE, Roche and Blueprint hereby agree as follows:
		

		
			At the end of Section 4.1.6, the following shall be inserted:
		

		
			Under the Agreement, Blueprint will transfer Library Compounds to Roche.  Roche will use the Library Compounds solely for Screening as outlined in the Agreement and for no other purpose.  Roche agrees not to analyze the Library Compounds for the purpose of determining the structures thereof.  
		

		
			Blueprint may also transfer Other Compounds and Collaboration Compounds to Roche.  Roche will use the Other Compounds solely as outlined in the Research Plan and for no other purpose.  Prior to exercising an Option Right for a given Collaboration Target, Roche will use the Collaboration Compounds for that Collaboration Target solely as outlined in the Research Plan and for no other purpose.  Prior to achieving Lead Series Identified Criteria, Roche agrees not to analyze the Other Compounds or Collaboration Compounds for the purpose of determining the structures thereof.
		

		
			The Screening and use of the Library Compounds, Other Compounds, and Collaboration Compounds by Roche under the Research Plan will be conducted at Roche’s research facilities.  None of the Library Compounds or Other Compounds will be transferred or sold to third parties.  Prior to exercising an Option Right for a given Collaboration Target, none of the Collaboration Compounds for that Collaboration Target will be transferred or sold to third parties, unless specified by the Research Plan.
		

		
			

		 

 

Roche and Blueprint further agree as follows:
		

		
			After the 4th paragraph of Section 4.1.5 of the Agreement, the following shall be inserted:
		

		
			A crystallographer at Roche (“Crystallographer”) shall be designated in writing by Roche to solve crystal structures of Library Compounds, Other Compounds, or Collaboration Compounds bound to Targets as specified in the Research Plan. Roche will produce crystals of the target kinase complexed with an inhibitor.  If the resulting electron density maps suggest that the x-ray structure of the kinase inhibitor complex can be determined, the project team will be informed.  The Crystallographer will not continue refinement of the structure until the project team has approved further refinement.  If the Crystallographer inadvertently solves for the structure of the inhibitor prior to approval, he or she will remain bound by the confidentiality provisions of this section.  If approved by the project team, the chemical structure of the inhibitor will disclosed to the Crystallographer who will then complete the refinement of the structure to reveal the kinase - inhibitor structure.  The Crystallographer shall independently handle the structural information regarding Library Compounds, Other Compounds, and Collaboration Compounds learned from solving such crystal structures; no structures of Library Compounds, Other Compounds, and Collaboration Compounds can be shared with any other individuals within Roche other than members of senior management specified on Appendix 4.1.5 acting in their decision making capacity and the Insulated Chemistry Experts.  For clarity, these structures cannot be used for any other purpose than specified in the Research Plan, including any research purpose.  Appropriate safeguards will be established by Roche that are intended to prevent any inadvertent disclosure or improper use of these structures and any structural information related to such structures. From Lead Nomination onwards and throughout Lead Optimization, the structures of Other Compounds and Collaboration Compounds in the Lead Optimization phase shall be shared with the Roche project team members (including Collaboration Compounds meeting Lead Series Identified Criteria, CLS Criteria and CCS Criteria).
		

		
			Roche and Blueprint further agree as follows:
		

		
			Appendix 1.38 shall be deleted in its entirety and replaced with the attached Appendix 1.38.
		

		
			All other terms defined in the Agreement are to be interpreted as defined therein, and all other terms of the Agreement are to remain in full force and effect.
		

		
			This Amendment may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.
		

		
			
		

		
			

		 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives.
		

		
			 
		

			
					
						Blueprint Medicines Corporation

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						/s/ Jeffrey Albers

					
					
						 

				
	
					
						Name: Jeffrey Albers

					
					
						 

				
	
					
						Title: Chief Executive Officer

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						F. Hoffmann-La Roche Ltd

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						/s/ Stefan Arnold

					
					
						/s/ Barbara Lueckel 

				
	
					
						Name: Stefan Arnold

					
					
						Name: Dr. Barbara Lueckel

				
	
					
						Title: Head Legal Pharma

					
					
						Title: Head of Research & Technologies Partnering

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						Hoffmann-La Roche Inc.

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						/s/ John P. Parise

					
					
						 

				
	
					
						Name: John P. Parise

					
					
						 

				
	
					
						Title: Assistant Secretary

					
					
						 

				

		
			 
		

		
			 
		

		
			
		

		
			

		 

 

Appendix 1.38
		

		
			Approved CROs
		

		
			 
		

		
			[...***...]Fifth Supplemental Indenture

 Exhibit 4.3 

SUPPLEMENTAL INDENTURE, (this “Supplemental Indenture”) dated as of May 10, 2016, by and among Aquaterra Corporation, a
corporation amalgamated under the laws of Canada, 4368479 Canada Limited, a corporation incorporated under the laws of Canada, and 1702922 Ontario Limited, a corporation incorporated under the laws of the Province of Ontario, each as a Guarantor
(the “Guaranteeing Subsidiaries”), Cott Beverages Inc., a Georgia corporation (the “Issuer”), the other Guarantors (as defined in the Indenture referred to herein), and Wells Fargo Bank, National Association, as
Trustee under the Indenture referred to below, Paying Agent, Registrar, Transfer Agent and Authenticating Agent (the “Agent”). 

W I T N E S S E T H: 
 WHEREAS,
the Issuer, each of the Guarantors, the Trustee and the Agent have heretofore executed and delivered an indenture dated as of June 24, 2014 (as amended, supplemented, waived or otherwise modified, the “Indenture”), providing
for the issuance of an aggregate principal amount of $525,000,000 of 5.375% Senior Notes due 2022 of the Issuer (the “Notes”); 

WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiaries shall execute and deliver to the Trustee a
supplemental indenture to which the Guaranteeing Subsidiaries shall unconditionally guarantee, on a joint and several basis with the other Guarantors, all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions
set forth herein and under the Indenture (the “Guarantee”); 
 WHEREAS, this Supplemental Indenture shall not result in a
material modification of the Notes for purposes of compliance with the Foreign Accounts Tax Compliance Act; and 
 WHEREAS, pursuant to
Section 9.1 of the Indenture, the Issuer, any Guarantor, the Trustee and the Agent are authorized to execute and deliver a supplemental indenture to add additional Guarantors, without the consent of any Holder; 

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged,
the Guaranteeing Subsidiaries, the Issuer, the other Guarantors, the Trustee and the Agent mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

ARTICLE I 
 DEFINITIONS 

SECTION 1.1. Defined Terms. As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recitals
hereto are used herein as therein defined. The words “herein,” “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any
particular section hereof. 

 ARTICLE II 

AGREEMENT TO BE BOUND; GUARANTEE 

SECTION 2.1. Agreement to be Bound. Each of the Guaranteeing Subsidiaries hereby becomes a party to the Indenture as a Guarantor and as
such will have all of the rights and be subject to all of the obligations and agreements of a Guarantor under the Indenture. 
 SECTION 2.2.
Guarantee. The Guaranteeing Subsidiaries agree, on a joint and several basis with all the existing Guarantors, to fully, unconditionally and irrevocably Guarantee to each Holder of the Notes and the Trustee and the Agent the Guaranteed
Obligations pursuant to Article X of the Indenture on a senior basis. 
 ARTICLE III 

MISCELLANEOUS 
 SECTION 3.1.
Notices. All notices and other communications to the Guaranteeing Subsidiary shall be given as provided in the Indenture to any Guarantor, at their address set forth below, with a copy to the Issuer as provided in the Indenture for notices to
the Issuer. 
 c/o Cott Corporation 

5519 West Idlewild Avenue 
 Tampa,
FL 33634 
 SECTION 3.2. Merger and Consolidation. None of the Guaranteeing Subsidiaries shall sell or otherwise dispose of all or
substantially all of its assets to, or consolidate with or merge with or into another Person (other than the Company, the Issuer or any Restricted Subsidiary that is a Guarantor or becomes a Guarantor concurrently with the transaction) except in
accordance with Section 4.1(f) of the Indenture. 
 SECTION 3.3. Release of Guarantee. This Guarantee shall only be
released in accordance with Section 10.2 of the Indenture. 
 SECTION 3.4. Parties. Nothing expressed or mentioned herein is
intended or shall be construed to give any Person, firm or corporation, other than the Holders, the Trustee and the Agent, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any
provision herein or therein contained. 
 SECTION 3.5. Governing Law. This Supplemental Indenture shall be governed by, and construed
in accordance with, the laws of the State of New York. 
 SECTION 3.6. Severability. In case any provision in this Supplemental
Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such
invalidity, illegality or unenforceability. 
 SECTION 3.7. Benefits Acknowledged. The Guaranteeing Subsidiaries’ Guarantee is
subject to the terms and conditions set forth in the Indenture. Each of the Guaranteeing Subsidiaries acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental
Indenture and that the guarantee and waivers made by it pursuant to this Guarantee are knowingly made in contemplation of such benefits. 

 SECTION 3.8. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except
as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all
purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby. 
 SECTION 3.9. The
Trustee and the Agent. Each of the Trustee and the Agent makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture or with respect to the recitals contained herein, all of which recitals are made solely
by the other parties hereto. 
 SECTION 3.10. Counterparts. The parties hereto may sign any number of copies of this Supplemental
Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective
execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be
their original signatures for all purposes. 
 SECTION 3.11. Execution and Delivery. Each of the Guaranteeing Subsidiaries agrees
that the Guarantee shall remain in full force and effect notwithstanding any failure to endorse on each Note a notation of any such Guarantee. 

SECTION 3.12. Headings. The headings of the Articles and the Sections in this Supplemental Indenture are for convenience of reference
only and shall not be deemed to alter or affect the meaning or interpretation of any provisions hereof. 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  

			
	COTT BEVERAGES INC.
		
	By:	 	

		 	  

	Name:	 	Shane Perkey
	Title:	 	Treasurer

  
 [Signature Page to
Supplemental Indenture 2022] 

 
			
	156775 CANADA INC.
	2011438 ONTARIO LIMITED
	804340 ONTARIO LIMITED
	967979 ONTARIO LIMITED
	CAROLINE LLC
	CLIFFSTAR LLC
	COTT CORPORATION
	COTT HOLDINGS INC.
	COTT VENDING INC.
	INTERIM BCB, LLC
	DS SERVICES OF AMERICA, INC.
	DS CUSTOMER CARE, LLC,
	as Guarantors
		
	By	 	

		 	  

	Name:	 	Shane Perkey
	Title:	 	Treasurer
	
	CALYPSO SOFT DRINKS LIMITED
	COOKE BROS HOLDINGS LIMITED
	COOKE BROS. (TATTENHALL). LIMITED
	COTT DEVELOPMENTS LIMITED
	COTT VENTURES LIMITED
	COTT VENTURES UK LIMITED
	MR FREEZE (EUROPE) LIMITED
	TT CALCO LIMITED,
	as Guarantors
		
	By	 	

		 	  

	Name:	 	Shane Perkey
	Title:	 	Treasurer

  
 [Signature Page to
Supplemental Indenture 2022] 

 
			
	COTT (NELSON) LIMITED
	COTT BEVERAGES LIMITED
	COTT EUROPE TRADING LIMITED
	COTT LIMITED
	COTT NELSON (HOLDINGS) LIMITED
	COTT PRIVATE LABEL LIMITED
	COTT RETAIL BRANDS LIMITED,
	as Guarantors
		
	By	 	

		 	  

	Name:	 	Jason Ausher
	Title:	 	Director

  
 [Signature Page to
Supplemental Indenture 2022] 

 
			
	COTT LUXEMBOURG S.Á R.L.
	COTT BEVERAGES LUXEMBOURG S.Á R.L,
	as Guarantors
		
	By	 	

		 	  

	Name:	 	Jerry Hoyle
	Title:	 	Class A Manager
		
	By	 	

		 	  

	Name:	 	Christophe Fender
	Title:	 	Class B Manager
	
	COTT UK ACQUISITION LIMITED,
	as a Guarantor
		
	By	 	

		 	  

	Name:	 	Jerry Hoyle
	Title:	 	Director

  
 [Signature Page to
Supplemental Indenture 2022] 

 
			
	AIMIA FOODS EBT COMPANY LIMITED
	AIMIA FOODS GROUP LIMITED
	AIMIA FOODS HOLDINGS LIMITED
	AIMIA FOODS LIMITED
	STOCKPACK LIMITED,
	as Guarantors
		
	By	 	

		 	  

	Name:	 	Shane Perkey
	Title:	 	Treasurer

  
 [Signature Page to
Supplemental Indenture 2022] 

 
			
	AQUATERRA CORPORATION,
	4368479 CANADA LIMITED,
	1702922 ONTARIO LIMITED,
	as the Guaranteeing Subsidiaries
		
	By	 	

		 	  

	Name:	 	Shane Perkey
	Title:	 	Treasurer

  
 [Signature Page to
Supplemental Indenture 2022] 

 
			
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee
		
	By:	 	

		 	  

	Name:	 	Raymond Delli Colli
	Title:	 	Vice President

  
 [Signature Page to
Supplemental Indenture 2022]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]